Rocket Pharmaceuticals Stock News

Rocket Pharmaceuticals Inc (RCKT) shares closed this week 20.5% higher than it did at the end of last week. The stock is currently down 11.5% year-to-date, down 68.2% over the past 12 months, and up 197.2% over the past five years. This week, the Dow Jones Industrial Average rose 0.4%, and the S&P 500 rose 0.6%. Trading Activity Shares traded as high as $20.90 and as low as $15.75 this week.Trading volume this week was 59.7% higher than the 10-day average and 80.3% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.7. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 9.0% The company's stock price performance over the past 12 months lags the peer average by 100.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

From Citizen Kane, chairman of the board Bernstein quips, its no trick to make a lot of money if what you want to do is make a lot of money. Downright laughable was Washington Posts catchy

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces Gaurav Shah, M.D., Chief Executive Officer, will participate in a fireside chat at the virtual 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, Feb. 16 at 10 a.m. ET. A live audio webcast of the presentation will be available under Events in the Investors sect

US stock futures traded higher this morning, with the Dow futures adding more than 200 points this morning. Investors, meanwhile, focused on some notable insider trades. When insiders purchase shares,

US stock futures traded higher this morning, with the Dow futures adding more than 200 points this morning. Investors, meanwhile, focused on some notable insider trades.

The biotech market has seen a massive influx of revenue due to the surging Covid pandemic.

Rocket Pharmaceuticals Inc (RCKT) shares closed 1.7% lower than its previous 52 week low, giving the company a market cap of $1B. The stock is currently down 5.9% year-to-date, down 63.9% over the past 12 months, and up 193.4% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 54.6% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 271.5% The company's stock price performance over the past 12 months lags the peer average by 112.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Rocket Pharmaceuticals Inc (RCKT) shares closed today at 0.7% above its 52 week low of $20.39, giving the company a market cap of $1B. The stock is currently down 5.9% year-to-date, down 63.9% over the past 12 months, and up 202.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 41.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 271.5% The company's stock price performance over the past 12 months lags the peer average by 107.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

A tough 2021 has small-cap stocks positioned for a potentially fruitful 2022. Analysts are most bullish on these 12 picks in the new year.

Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout 2021 amid delays in p

Biotech stocks remain poised to eke out modest gains for 2021 after the stellar gains of the previous year. COVID-19 drug and vaccine developers experienced volatility throughout 2021 amid delays in p

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)s stock price gapped up prior to trading on Monday . The stock had previously closed at $21.52, but opened at $22.34. Rocket Pharmaceuticals shares last traded at $21.98, with a volume of 699 shares changing hands. Several research analysts have commented on RCKT shares. Zacks Investment Research lowered Rocket Pharmaceuticals from [] The post Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Gap Up to $21.52 appeared first on ETF Daily News .

Rocket Pharmaceuticals (NASDAQ:RCKT) had its price target lifted by Chardan Capital from $56.00 to $60.00 in a research note published on Wednesday morning, Price Targets.com reports. The firm currently has a buy rating on the biotechnology companys stock. A number of other analysts have also issued reports on the company. Lifesci Capital restated an outperform []